You are here
Merck weighing acquisition of Cubist for more than US$7b: sources
DRUGMAKER Merck & Co is in talks to acquire the biopharmaceuticals company Cubist for more than US$7 billion, according to people briefed on the matter.
The deal, if announced, would represent another multibillion-dollar health care transaction in a banner year for
- CALL +65 6388 3838
- EMAIL firstname.lastname@example.org